Read between the lines when you get price points
Often, companies will tell you you're paying $0.10 per sample, but "you can't
just go off their numbers. You have to really cost it out," says Jeanette Papp,
director of the UCLA Genotyping and Sequencing Core Facility. Some companies will
sell enough primer for 4,000 samples even if you don't need it. Anticipate the
sample quality and whether you need to rerun the samples, a factor that companies
don't account for.
Watch for the grey area in medium throughput
The decision on how you're going to genotype SNPs will change based on how
many you have. The window between 30 SNPs and 300 can be tricky because it's not
entirely clear what platform you should be using, says Peter Zandi. Sequenom
instruments can work in that range, but users must do the cost comparison, he adds.
Talk to a biostatistician before you start
"You need to make sure you have the power to be able to answer your question
before you ask it," says Seth Crosby, director of translational research at
Washington University in St. Louis. The number of cases and controls you might need
for an association study will vary depending on several factors, such as the number
of SNPs you're looking at, how many cases you have, and whether in a human study
your cases and controls are from the same families.
Aim for consistency in DNA quality and concentration
Even though most multiplexing platforms nowadays can handle different
concentrations of DNA, keep the samples consistent, even if they're consistently low
quality, Papp says. This isn't always obvious to new users who are multiplexing.
Bigger and newer isn't always better
If you're thinking of using a newer high throughput platform, be sure to
check the minimum amount of DNA required for the platforms on the market today.
Hayes' group just started working with Illumina's Bead Xpress and Beadstation. These
require 100-200 ng of DNA, more than five times the DNA requirement using a Sequenom
instrument, says Hayes. "This is a major problem for our research," Hayes says.
"That's quite a lot of DNA when resources are at a premium, yet the number of
markers one can screen are large," she says.